| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cee50211914c19ccaabc85c6bc50fb72 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-16134
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2469-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-045
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5258
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55505 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-582
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6854
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5091
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5044 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50 |
| filingDate |
2013-03-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2018-06-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1707c1b797d937e5db8bf8e42304d155
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_50dbd63e66606a461f55f021a50b8b0a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d0e01a48ddabce54c48fdc9f2096cd56 |
| publicationDate |
2018-06-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-10006096-B2 |
| titleOfInvention |
Methods for detection of anti-cytomegalovirus neutralizing antibodies |
| abstract |
The present disclosure provides methods useful for determining levels of HCMV infection in host cells and, by extension, determining levels of neutralizing antibodies present in a sample. The present disclosure encompasses the recognition that HCMV viruses that have a fluorescent moiety permit detection of viral infection (e.g., by assessing fluorescence in cells after contacting the host cell with the virus). In some embodiments, levels of HCMV infection are determined by fluorescence detection where the virus has been preincubated with a test sample (e.g., a serum sample) from a subject. In some embodiments, the subject has been administered a candidate HCMV vaccine. |
| priorityDate |
2012-03-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |